Accelerate Diagnostics (Accelerate Diagnostics) Total Liabilities : $51.25 Mil (As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

What is Accelerate Diagnostics Total Liabilities?

Accelerate Diagnostics's Total Liabilities for the quarter that ended in Dec. 2023 was $51.25 Mil.

Accelerate Diagnostics's quarterly Total Liabilities declined from Jun. 2023 ($88.54 Mil) to Sep. 2023 ($74.36 Mil) and declined from Sep. 2023 ($74.36 Mil) to Dec. 2023 ($51.25 Mil).

Accelerate Diagnostics's annual Total Liabilities declined from Dec. 2021 ($118.12 Mil) to Dec. 2022 ($87.28 Mil) and declined from Dec. 2022 ($87.28 Mil) to Dec. 2023 ($51.25 Mil).

Accelerate Diagnostics Total Liabilities Historical Data

The historical data trend for Accelerate Diagnostics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerate Diagnostics Total Liabilities Chart

Accelerate Diagnostics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

141.80

156.24

118.12

87.28

51.25

Accelerate Diagnostics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															87.28	89.73	88.54	74.36	51.25

Accelerate Diagnostics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Accelerate Diagnostics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	12.034	+	(36.934	+	1.164
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	1.122	+	0)
	=	51.25

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	31.366	-	-19.888
	=	51.25

Accelerate Diagnostics's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	12.034	+	(36.934	+	1.164
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	1.122	+	0)
	=	51.25

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	31.366	-	-19.888
	=	51.25

Accelerate Diagnostics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Accelerate Diagnostics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Accelerate Diagnostics (Accelerate Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Accelerate Diagnostics Inc (NAS:AXDX) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

AXDX:Mexico 1A80:Germany

Address

3950 South Country Club Road, Suite 470, Tucson, AZ, USA, 85714

Website

https://www.acceleratediagnostics.com

Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.

Executives

David Patience	officer: Chief Financial Officer	C/O ACCELERATE DIAGNOSTICS, INC., 3950 S. COUNTRY CLUB ROAD, SUITE 240, TUCSON AZ 85714
Jack Phillips	director, officer: PRESIDENT AND CEO	11731 YALE DR, CARMEL IN 46032
Larry Michael Mertz	officer: Chief Technology Officer	3950 S. COUNTRY CLUB ROAD, TUCSON AZ 85714
Marran H. Ogilvie	director	599 LEXINGTON AVENUE, NEW YORK NY 10022
Jennifer Regan	director	C/O ACCELERATE DIAGNOSTICS, INC., 3950 S. COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714
Mark S. Black	director	3950 S. COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714
Steven Reichling	officer: CFO	7000 NORTH BROADWAY, BUILDING 3-307, DENVER CO 80221
Ron Price	officer: SVP & HEAD OF COM OPS AMERICAS	3950 SOUTH COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714
Wayne Burris	director	3451 PLANO PARKWAY, LEWISVILLE TX 75056
Hany Massarany	director	1910 INNOVATION PARK DR, TUCSON AZ 85737
Jack W Schuler	director, 10 percent owner	100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Mark C Miller	director	C/O STERICYCLE INC., 28161 N KEITH DRIVE, LAKE FOREST IL 60045
Ten Brink Frank Jm	director	C/O STERICYCLE INC, 28161 N KEITH DR, LAKE FOREST IL 60045
Charles M Watts	director	3950 SOUTH COUNTRY CLUB, SUITE 470, TUCSON AZ 85714
Louise Francesconi	director	870 WINTER STREET, WALTHAM MA 02451